Last reviewed · How we verify
NCT06331533
Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea
Phase 4 trial testing Botulinum toxin A in Erythematotelangiectatic Rosacea in 30 participants. Completed in 1 June 2023.
1 May 2023
Quick facts
| Lead sponsor | Istanbul Training and Research Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 November 2022 |
| Primary completion | 1 May 2023 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Botulinum toxin A — full drug profile →
- Placebo
Conditions studied
- Erythematotelangiectatic Rosacea — all drugs for Erythematotelangiectatic Rosacea →
Sponsor
Istanbul Training and Research Hospital
Who can join
Adults 18 to 60, any sex, with Erythematotelangiectatic Rosacea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06331533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Botulinum toxin A
Trials testing the same drug.
- NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
- NCT06470581 — Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A · NA · not yet recruiting
- NCT06814288 — The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment · Phase 2 · active not recruiting
- NCT06315790 — Safety and Efficacy of Botulinum Toxin A in Patients With Trigeminal Neuralgia · Phase 3 · unknown
- NCT06878482 — Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease · Phase 4 · recruiting
Other recruiting trials for Erythematotelangiectatic Rosacea
Currently open trials in the same condition.
- NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
Other Istanbul Training and Research Hospital trials
Trials by the same sponsor.
- NCT07499713 — Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata · enrolling by invitation
- NCT07335822 — The Effectiveness of Low-Level Laser Therapy in the Treatment of Meralgia Paresthetica · NA · recruiting
- NCT07363187 — Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation · not yet recruiting
- NCT07415291 — CNN-Based AI Versus Physicians for Solitary Skin Lesion Diagnosis · active not recruiting
- NCT07150702 — Effects of Close Follow-up on Patients With Low Back Pain · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06331533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Training and Research Hospital
- Last refreshed: 29 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06331533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing